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Background: Chronic myalgia is associated with higher muscle levels of certain algesic biomarkers. The aim of this
study was to investigate if hypertonic saline-induced jaw myalgia also leads to release of such biomarkers and if
there were any sex differences in this respect.
Methods: Healthy participants, 15 men and 15 aged-matched women (25.7 ± 4.3 years) participated. Intramuscular
microdialysis into masseter muscles was performed to sample serotonin (5-HT), glutamate, lactate, pyruvate, glucose
and glycerol. After 2 hours 0.2 mL hypertonic saline (58.5 mg/mL) was injected into the masseter on one side and
0.2 mL isotonic saline (9 mg/mL) into the contralateral masseter close to the microdialysis catheter. Microdialysis
continued for 1 hour after the injections. Pressure pain thresholds (PPT) and pain were assessed before and after
injections.
Results: The median (IQR) peak pain intensity (0–100 visual analogue scale) after hypertonic saline was 52.5 (38.0)
and after isotonic saline 7.5 (24.0) (p < 0.05). 5-HT, glutamate and glycerol increased after hypertonic saline injection
(p < 0.05). Lactate, pyruvate and glucose showed no change. PPT after microdialysis was reduced on both sides
(p < 0.05) but without side differences. Pain after hypertonic saline injection correlated positively to 5-HT (p < 0.05)
and negatively to glycerol (p < 0.05).
Conclusions: 5-HT, glutamate and glycerol increased after a painful hypertonic saline injection into the masseter
muscle, but without sex differences. Since increased levels of 5-HT and glutamate have been reported in chronic
myalgia, this strengthens the validity of the pain model. Glycerol warrants further investigations.
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Chronic temporomandibular disorder (TMD) pain has a
prevalence of approximately 10–15% in the adult popu-
lation [1,2]. Myofascial TMD is the most frequent type
of TMD pain in the orofacial region and is often accom-
panied by restricted mouth opening, pain upon chewing,
muscle soreness, pain referral and headache which re-
duces patients’ quality of life [3,4]. The prevalence of
TMD is known to be 1.5 to 2 times higher amongst* Correspondence: sofia.louca@ki.se
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in any medium, provided the original work is pwomen than men [5,6]. However, the etiology of myofas-
cial TMD and its higher prevalence in women is still not
fully understood.
Stress- related muscular hyperactivity, such as tooth
clenching/grinding, is often suggested to contribute to the
etiology of myofascial TMD [7,8] although no simple rela-
tionship between electromyographic (EMG) activity and
TMD pain has been noted [9,10]. Epidemiological studies
also showed a greater likelihood of myofascial pain in the
presence of self-reported tooth clenching [11,12]. Further-
more, it has been suggested that muscular hyperactivity
could cause pain by mechanical overloading accompanied
by disturbed local blood flow [13].n Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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inflammatory, as well as, neuroactive biomarkers, such
as neuropeptides, bradykinin, protons, serotonin (5-HT),
glutamate and cytokines. When these inflammatory and
neuroactive biomarkers activate receptors on peripheral
sensory afferents, for instance 5-HT3, N-methyl-D-
aspartic acid (NMDA), 2-amino-3-(3-hydroxy-5-methyl-
isoxazol-4-yl) propanoic acid (AMPA) and kainate
receptors, they induce pain [14,8].
Several studies have shown that patients with chronic
myalgia have higher interstitial levels of 5-HT and glu-
tamate in the masseter and trapezius muscles compared
to healthy controls, and that muscle levels correlated to
pain levels [15-20]. Intramuscular injection of serotonin
and glutamate further evoked pain [21,22]. Thus these
substances can be regarded as potential biomarkers for
chronic myalgia.
In addition, interstitial levels of lactate and pyruvate
increased in painful trapezius muscle, which may also in-
dicate a role for metabolic markers in chronic myalgia
[17,18,23,24]. Only one previous study has studied the re-
lease of lactate and pyruvate in myofascial TMD pain and
found similar levels compared to pain-free controls [25].
To better understand and widen the knowledge about
chronic pain, use of experimental pain models that
mimic pain conditions are necessary. Intramuscular in-
jections of hypertonic saline are frequently used to
mimic human myalgia and regarded as a valid model of
myalgia, in the orofacial region [26]. This experimental
pain model has an acute character and causes a short
lasting, distinct sensation of deep, diffuse pain, and pain
referral [27-30]. However, to increase validity of the ex-
perimental pain model, the same biomarkers as in clin-
ical pain should be increased after hypertonic saline
injections. Therefore the main aim of this study was to
investigate if jaw muscle pain induced by hypertonic sa-
line lead to a release of muscle biomarkers. A second
aim was to investigate if there were any sex differences
related to the release of mediators. We hypothesized that
release of several inflammatory mediators, such as 5-HT,
glutamate and other biomarkers of metabolic activity,
such as lactate, pyruvate, glucose and glycerol were sig-
nificantly higher in hypertonic saline-induced pain and
that there was higher release in women than in men.
Methods
Participants
Healthy participants of both sexes participated in the
study. The participants were recruited by advertisements
but additionally from colleagues and students at the De-
partment of Dental Medicine at the Karolinska Institutet,
Sweden, where the study was conducted. No students
from current courses given by the authors were included.
Inclusion criteria were age over 18 years and good generalhealth. Exclusion criteria were any current orofacial pain,
diagnosed systemic muscular or joint diseases, such as
fibromyalgia, rheumatoid arthritis, whiplash-associated
disorder, neuropathic pain or neurological disorders,
pregnancy or lactation, high blood pressure and use of
antidepressants or analgesics during the last three days.
According to the power calculation, inclusion of 26
participants would be sufficient to detect a statistically
significant difference of 20% (SD 30%) in biomarker
level between interventions at a significance level of 5%
with a power of 90%. In order to compensate for drop-
outs/missing data four additional participants were
included.
The project followed the guidelines according to the
Declaration of Helsinki as well as Good Clinical Practice
and was approved by the regional ethical review board
in Stockholm (2008/362-31) and the local radiology
committee (Dnr 11/08) at Karolinska University Hospital
in Huddinge, Sweden. All participants received written
and verbal information about the study before participat-
ing and gave their written consent.
Experimental protocol
This study used a randomized, double-blinded and
placebo-controlled design in which hypertonic saline was
injected into one of the masseter muscles and isotonic sa-
line (control) on the contralateral side. Randomization of
sides for injection was performed by a computer (www.
randomization.com). The preparation and blinding of
syringes was made by a researcher not participating in the
study and the syringes were marked with the participants
study number. Since hypertonic saline and isotonic saline
have identical appearance, both the participant and the in-
vestigator were blinded.
In order to confirm that the participants were eligible
for inclusion in the study screening was performed in-
cluding a clinical examination according to the Research
Diagnostic Criteria for TMD (RDC/TMD) Axis I [31].
After inclusion in the study the participants filled in in-
struments regarding anxiety including the State-Trait
Anxiety Inventory (STAI-trait) [32] and stress by the
Perceived Stress Scale (PSS) [33]. Further, the pressure
pain threshold (PPT) was assessed bilaterally over the
masseter muscles and over the right forefinger.
Participants were placed in a conventional dental chair
and were instructed to lie as still as possible during the ex-
periment and to avoid talking. After baseline registrations
and local anesthesia bilateral microdialysis was performed
over 3 hours. The participants received a hypertonic saline
injection into one of masseter muscle and an isotonic sa-
line injection on the contralateral side, and pain intensity,
pain duration and pain area evoked by the injections were
registered. After microdialysis, PPT was assessed again at
the same sites (Figure 1).
Figure 1 Flow chart of the experimental setting. The figure shows the time points (minutes) for the clinical examination, assessment of
pain intensity, pressure pain threshold, questionnaires (STAI, PSS-14, MPQ) including pain drawing, microdialysis and dialysate sampling in 15
healthy men and 15 age-matched women. BEF = Before microdialysis; BL = Baseline at 120 minutes; RDC/TMD = Research diagnostic criteria;
STAI = State-Trait Anxiety Inventory; PSS = Perceived Stress Scale.
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A 0–10 numeric rating scale (NRS) with the end-points
marked “no pain” and “the worst pain experienced” was
used to assess pain in the masseter muscle before the
start of the study to ensure that all participants were
pain free, in that they graded their pain as 0, and there-
after every 20th minute during microdialysis when the
dialysate microvials were changed.
The PPT was assessed with an electronic algometer
(Somedic Sales AB, Höör, Sweden) with a standardized
pressure rate of 50 kPa per second [15,34]. The tip of the
algometer was 1 cm2 and covered with a 1-mm thick
rubber pad. Pressure was administrated on the most
prominent point of the masseter muscle, which was
verified during contraction and the PPT was assessed in the
relaxed muscle. The participants were instructed to press
the signal button immediately when the sensation of pres-
sure turned into pain. The right forefinger was used as a
reference. All recordings were performed three times with
an interval of 2 minutes between measurements. The aver-
age of the three recordings was used in statistical analyzes.
State-Trait Anxiety Inventory (STAI)
The STAI is an instrument used to measure anxiety in
adults. It comprises two twenty-item scales that deter-
mine two types of anxiety [32,35]. The first measures
state anxiety, which is anxiety about an event, and the
second measures trait anxiety, which is anxiety level as a
personal characteristic. Questions have a range of four
possible responses, rated on a scale from 1–4. Several of
the items had reversed scoring. In this study the focus
was on the more general and long-standing quality of
trait anxiety (STAI-trait), which is very common charac-
teristic in patients with chronic pain [32,35]. Scores
ranged from 20 to 80, with higher scores indicating
higher levels of anxiety. If the scores were ≤ 30 the pa-
tient showed no or low signs of anxiety but if the scores
were > 30, patients showed moderate to high signs of
anxiety.Perceived stress scale-14 (PSS-14)
The PSS questionnaire is a widely and commonly used
questionnaire of psychological nature that measures the
perception of stress. It consists of 14 stress-related ques-
tions of a general nature, including questions regarding
feelings and thoughts during the last month, and also
what situations in life that are perceived as stressful and
the current levels of experienced stress. The question-
naire was used according to Cohen and co-workers [33]
by reversing the scores on the seven positive items and
then summing the values of the 14 questions. The PSS
questionnaire had a total sum of 56. A score below
23.67 has been considered as normal in healthy partici-
pants [33,36].
Microdialysis
Intramuscular microdialysis in the masseter muscle was
performed to sample 5-HT, glutamate, lactate, pyruvate,
glucose and glycerol, and to estimate nutritive muscle
blood flow. The most prominent point of the masseter
muscle was chosen and verified by palpation as the
participants were instructed to clench. To anaesthetize
the skin overlying the muscle a local anaesthetic patch
(EMLA® patch, lidocaine/prilocaine 25 mg/25 mg, Astra-
Zeneca AB, Södertälje, Sweden) was applied for 30 -
minutes. The EMLA® patch was then removed and the
skin surface thoroughly cleaned with injection swabs
(70% isopropyl alcohol). A sterile 6-mm thick plastic
plate (10 × 40 mm) was placed over the chosen point of
the masseter muscles and fixed with surgical tape. The
plate contained two 1.3-mm wide canals, 10 mm apart,
one at 90° angle to the surface and the other at 45°
angle. A standard catheter (Ø 1.3 × 32 mm, Venflon,
BOC Ohmeda AB, Helsingborg, Sweden) was inserted
intramuscularly parallel to the muscle fibers to a depth
of approximately 20 mm from the skin surface, guided
by the 45° canal of the plastic plate. When inserting the
catheter a slight resistance was typically felt upon pene-
tration of the muscle fascia, after it was inserted 12 mm
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during insertion of the microdialysis probe (see below).
The catheter was then withdrawn 10 mm, the needle re-
moved and the external part of the catheter cut with a
scalpel at its entrance into the plastic plate. In this man-
ner the tip of the plastic tube was placed approximately
10 mm deep into the muscle [37].
A sterile flexible microdialysis probe (Ø 0.5 mm;
membrane length 10 mm, total length 30 mm; molecular
cut off: 6 kDa MAB 11, Microbiotech AB, Stockholm,
Sweden) was inserted into the muscle via the catheter to
its full length to ensure that the whole membrane pro-
truded outside the catheter. The probe was perfused
(5 μl/min) with a Ringer-Acetate solution containing
0.5 mM Ringer-lactate with a 2-ml syringe connected to
a micro infusion pump (MAB 140, Microbiotech AB,
Stockholm, Sweden). A volume of 3.0 μL [14C]-lactate
(specific activity: 7.4 MBq/mL; PerkinElmer Life
Sciences, Boston, MA, USA) was added to the perfusion
medium to determine the relative recovery (RR) of the
mediators [38] and 3.0 μL 3H2O to estimate blood flow
[19,39]. Samples of 120 μL were collected every 20 mi-
nutes in 200-mL capped microvials. The samples were
immediately frozen (−70°C).
The whole microdialysis experiment lasted for 3 hours.
After 2 hours of stabilization (trauma phase), hypertonic
or isotonic saline was injected into the masseter. Micro-
dialysis continued for 1 hour after the injections. When
the microdialysis was finished the probe and the plastics
were removed as a unit and the membrane of the probe
was checked to make sure that no damaged occurred to
it and that the whole membrane protruded outside the
catheter.
Injections
Two standard disposable 19 mm needles (Neofly, BOC
Ohmeda AB,) with a diameter of 0.4 mm were used for
injection of test substances and inserted to their full
length into each of the masseter muscles guided by the
90° canal of the plastic plate. The needles were inserted
into the muscles directly after probe insertion to prevent
any pain caused by the needle that would interfere with
any pain from the injections. By using the guide, the
needle and the probe were in close proximity in the
muscle, as described previously [37].
Simultaneous bilateral injections of 0.2 mL sterile
hypertonic saline (58.5 mg/mL NaCl, Karolinska Univer-
sity Hospital Pharmacy) into the masseter muscle on
one side and 0.2 mL isotonic saline (NaCl 9 mg/mL,
Fresenius Kabi, Uppsala, Sweden) into the contralateral
masseter muscle was assured with the aid of an infusion
pump (Harvard Infusion Pump 22, Harvard Apparatus,
Edenbridge, UK). The substances were injected over
10 seconds using an infusion rate of 1200 μL/min.A 100-mm visual analogue scale (VAS) with the end-
points 0 = no pain and 100 = the worst pain experienced
was used to evaluate pain intensity in the masseter mus-
cles after injections. This was done every 15th second
until pain had subsided, to a maximum time of 300 sec-
onds [34]. From these measurements, individual max-
imum pain intensity (VAS peak) and pain duration were
calculated. Pain duration was defined as the pain
assessed by the participants immediately after injections
until it had faded away, according to a previous study
[34]. Pain drawings of the lateral side of the head (each
side separately) were also used in order to register the
pain area (au) including the maximum pain distribution
after the injections.
Analyzes
The first 2 hours of the microdialysis were regarded as a
trauma phase and no dialysate samples were analyzed.
The microdialysate samples were analyzed at the
Painomics Laboratory, Rehabilitation Medicine, Depart-
ment of Medical and Health Sciences, Linköping Univer-
sity, Sweden. The concentrations of 5-HT were analyzed
with high-pressure liquid chromatography, with electro-
chemical detection as previously has been described
[18]. The detection limit was 20 fmol/10 μL.
Other biomarkers (glutamate, glucose, lactate, pyru-
vate and glycerol), were analyzed with the ISCUS®
analyzer (ISCUS, Dipylon Medical AB, Solna, Sweden).
The limits of detection (LOD) were 1.0 μmol/L for glu-
tamate, 0.1 mmol/L for glucose and lactate, 10 μmol/L
for pyruvate and 0.22 mg/mL for glycerol. Samples with
concentrations below 50% of LOD were reported as hav-
ing the same concentration as LOD, whilst samples with
concentrations above 50% of LOD, the concentration
obtained was reported.
To determine the RR, 5 μL of each dialysate and per-
fusate was pipetted into a counting vial containing 3 mL
scintillation fluid (High-flash Point, Universal LSC-
Cocktail, ULTIMA GOLD™, PerkinElmer, Inc.) and vor-
texed. The counts per minutes (cpm) for [14C]-lactate
and 3H20 were analyzed in a liquid scintillation beta
counter (Beckman LS 6000TA; Beckman Instruments,
Inc., Fullerton, CA, USA). RR was calculated as (cpmp-
cpmd)/cpmp, where cpmp and cpmd were cpm in the
perfusate and dialysate, respectively. The RR calculation
describes the ratio between the actual concentration in
the muscle tissue and the concentration of the dialysates.
Interstitial concentrations (Ci) were calculated for glu-
tamate, glucose, lactate, pyruvate and glycerol as Ci = [Cd -
Cp]/ RR +Cp, where Cd was the dialysate concentration
and Cp was the perfusate concentration [33,38]. Nutri-
tive blood flow was calculated using 3H2O with the for-
mula 1/(cpmd/cpmp), where cpmd was
3H2O counts per
min in the dialysate and cpmp, in the perfusate [19,39]. RR
Table 1 The median (IQR) Perceived stress (PSS) and Trait
Anxiety (STAI-trait) at baseline
PSS STAI-trait
All 15.5 (10.0) 31.0 (6.8)
Men (n = 15) 15.0 (8.3) 31.5 (5.0)
Women (n = 15) 16.0 (10.8) 30.0 (8.8)
IQR = interquartile range (75 percentile minus 25 percentile).
There were no significant differences between sexes.
Figure 2 Pain intensity on the hypertonic saline side and
control side. Graph showing the median (IQR) pain intensity
according to VAS at the hypertonic saline and the control sides
throughout the experiment. Before injection there were no
differences between sides. After injections, the pain intensity was
significantly higher and the pain duration was significantly longer on
the side injected with hypertonic saline (Mann Whitney
U-test; p < 0.05).
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tire microdialysis.
Statistics
Data were analyzed with SigmaPlot for Windows, ver-
sion 11 (Systat Software Inc., Chicago, IL, USA) and
SPSS software version 15.0 (SPSS Inc. Chicago, IL,
USA). Non-parametric statistics were used to analyze
the substances since they were not normally distributed
and attempts to transform data did not change this. For
descriptive statistics median and interquartile range
(IQR) were used. Friedman test was used to analyze
changes in substances and pain levels over time at each
side separately. Bonferroni correction was used as post-
hoc test when the Friedman test indicated a significant
difference. To analyze differences between hypertonic
saline and control sides at the different time points, the
Mann–Whitney U-test was used. In addition the max-
imum pain intensity (VAS peak) induced by the injec-
tions was compared between sides with Mann–Whitney
U-test.
Differences in PPTs between sides before and after mi-
crodialysis and differences between sexes were analyzed
with unpaired t-test. The Mann Whitney U-test was
used to test the differences in VAS peak and pain area
between sides and differences in these variables between
sexes. Also differences between sexes in STAI-trait and
PSS-14 scores were tested with the Mann Whitney U-
test.
Spearman’s correlation test, adjusted for multiple test-
ing with Bonferroni correction, was used for analyzes of
significant correlations between NRS pain and release of
biomarkers at 140 minutes. For all tests the level of sig-
nificance was set to p < 0.05.
Results
Thirty healthy participants, 15 men and 15 aged- matched
women, with a mean age of 25.7 (SD 4.3) years partici-
pated in the study. None of the subjects dropped out.
The PSS and STAI-trait questionnaires indicated stress
and anxiety levels within the normal range in both the
men and women (Table 1).
Pain evoked by insertion of the microdialysis probe
No participant reported any pain before microdialysis.
The catheter and microdialysis probe induced a small
degree of pain on both sides in 10 out of 30 participants.
Twenty minutes after probe insertion the median (IQR)
pain for those participants was NRS 1 (1.0). The pain
levels during the trauma phase, for each participants
were 0 (0) on both sides at all time points, except of
hypertonic saline at 20 min, where it was 0 (0.8) and on
the control side at 20 min as well as 40 min where it
was 0 (1.0). No significant differences between sideswere found at any time points during the stabilization
period (before injections).
Pain characteristics after injections
Hypertonic saline injection evoked pain of moderate in-
tensity (p < 0.001) that lasted for more than 5 min,
whereas isotonic saline induced only minor and very
short-lasting pain (p < 0.001). The post-hoc test showed
that the intensity was significantly higher at the hypertonic
saline side 0–420 seconds after injections (Figure 2). The
VAS peak was significantly higher, the pain duration sig-
nificantly longer and the pain area significantly larger on
the side injected with hypertonic saline compared to the
control side (Table 2 and Figure 3).
Pressure pain thresholds
The PPTs before and after microdialysis are shown in
Table 3. There were no significant differences in baseline
PPT values between masseter muscle sides. After com-
pletion of the microdialysis the PPT on the hypertonic
saline side decreased by 18% and on the control side by
27% compared to baseline. No significant difference was
Table 2 The median (IQR) peak pain (VAS), pain duration
(s) and pain area (au) after injections
Hypertonic saline side Control side
Peak pain
All 52.5 (38.0) 7.5 (24.0)*
Men 50.0 (30.3) 0.0 (24.3)*
Women 56.0 (50.5) 15.0 (22.0)*
Pain duration
All 345 (150) 8 (45)*
Men 405 (170) 0 (64)*
Women 315 (131) 15 (45)*
Pain area
All 54 (65.0) 0 (3.0)*
Men 46 (69.3) 0 (2.3)*
Women 60 (87.8) 0 (5.5)*
Table shows data from thirty healthy participants, 15 men and 15
aged-matched women.
IQR = interquartile range (75 percentile minus 25 percentile) VAS = 100 mm
visual analogue scale * = significant difference between sides (p < 0.001). There
were no significant differences between sexes.
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microdialysis.
Release of biomarkers, relative recovery and blood flow
The levels of mediators are shown in Figure 4. The level
of 5-HT changed significantly over time (p < 0.05) on the
hypertonic saline side. The post-hoc test showed a sig-
nificant increase at 140 minutes, corresponding to the
first dialysate obtained after injection of hypertonic sa-
line, compared to baseline (Figure 4). There were no
changes in the 5-HT levels on the control side at any
time-point (Figure 4A).Figure 3 Pain distribution during experimental pain in the masseter m
after bilateral injections of hypertonic saline on one side and isotonic saline
15 age-matched men). The red areas show the pain distribution in women
was significantly larger after injection of hypertonic saline than control (MaThere was a significant difference in glutamate over
time (p < 0.05; Friedman test) on the hypertonic saline
side. The post-hoc test showed a significant increase at
140 minutes compared to baseline. There were no sig-
nificant time differences on the control side (Figure 4B).
Glycerol changed significantly over time (p < 0.05; Friedman
test) and was increased at the time point 140 minutes
(p < 0.05) on the hypertonic saline side. However, no
changes were found on the control side (Figure 4C).
None of the mediators lactate, pyruvate and glucose, dif-
fered significantly over time or between sides (Figures 4D-
3F). Neither were there any significant differences in any
of the mediators on the control side. The mean RR and
blood flow are shown in Table 4. The mean RR varied be-
tween 22 (14)% and 31 (9)% on the hypertonic saline side,
and between 19 (10)% and 37 (12)% on the control side.
Blood flow did not differ between sides or change as a
consequence of injections.
Correlations between pain and biomarker levels
The NRS pain intensity at 140 minutes on the hyper-
tonic saline side correlated positively to the 5-HT level
(rs = 0.408; n = 27, p = 0.034) and negatively to the gly-
cerol level (rs = −0.399; n = 28, p = 0.035) in the first di-
alysate sampled after injection (120–140 minutes).
There were also significant negative correlations on the
control side between NRS pain intensity and glutamate
(rs = −0.551; n =28, p = 0.003), glycerol (rs = −0.407; n =
28, p = 0.032) and lactate (rs = −0.448; n = 28, p = 0.017)
levels at 140 minutes.
Sex differences
There were no differences in STAI-trait or PSS levels be-
tween sexes (Table 1). The baseline PPTs were significantlyuscle. Figures showing the pain distribution in the masseter muscle
on the contralateral side in 30 healthy participants (15 women and
and the blue areas indicate the pain spread in men. The pain area
nn Whitney U-test; p < 0.05).
Table 3 The mean (SD) pressure pain threshold (PPT; kPa) of the masseter muscles before and after microdialysis
Hypertonic saline side Control side p-values between sides Reference point
Before
All 283.1 (82.6) 299.0 (185.0) 0.619 747.4 (217.8)
Men 318.0 (70.5)¤ 291.2 (70.2) 0.306 836.1 (193.7)
Women 245.6 (80.1) 307.4 (261.3) 0.308 658.7 (209.4)
After
All 232.1 (83.8)* 217.5 (85.5)* 0.407 742.0 (193.2)
Men 250.1 (83.4)* 234.6 (96.3) 0.642 766.8 (194.6)
Women 214.1 (83.0) 200.4 (72.4) 0.634 717.1 (195.2)
Data from thirty healthy participants, 15 men and 15 aged-matched women.
* = significantly lower PPT after microdialysis (p < 0.05).
¤ = significantly higher PPT compared to women (p < 0.05).
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(p = 0.023) but not on the isotonic saline side (p = 0.106).
The PPT of the index finger did not differ between sexes.
The PPTs assessed after microdialysis had decreased on the
hypertonic side in men (p = 0.023) but not on the isotonic
saline side (p = 0.076), whereas there were no significant
changes in the women (p = 0.308 for the hypertonic saline
side and p = 0.121 for the isotonic saline side) (Table 3).
Pain intensity, pain duration and pain area evoked by the
injections did not differ between sexes (Table 2 andFigure 4 Release of biomarkers in the masseter muscle during experi
glycerol (C), puruvate (D), lactate (E) and glucose (F) during the baseline (B
There was a significant increase of serotonin and glutamate on the hyperto
140 minutes compared to baseline (Bonferroni post-hoc test; p < 0.05), but
time point 140 minutes (Bonferroni post-hoc test; p < 0.05) on the hyperto
pyruvate and glucose show no significant increase.Figure 3). Furthermore there were no differences in the
levels of 5-HT, glutamate, lactate, pyruvate, glucose or gly-
cerol between sexes at any time point (data not shown).
Discussion
This study investigated if experimentally induced muscle
pain by hypertonic saline injection into the masseter
muscle lead to a release of muscle biomarkers, sampled
using intramuscular microdialysis. The main findings
were that 5-HT, glutamate and glycerol levels increasedmental pain. Graph shows the release of serotonin (A), glutamate (B),
L), experimental (Ex) and recovery (Rec) phases of the microdialysis.
nic saline side over time (Friedman test; p < 0.05) and at time point
no change on the control side. Glycerol increased significantly at the
nic saline side but not the control side. The other substances; lactate,
Table 4 The mean (SD) relative recovery (%) and blood
flow (%) in the masseter muscle during microdialysis









20 31 (9) 43 (19) 37 (12) 41 (22)
40 27 (9) 43 (18) 29 (14) 42(22)
60 28 (9) 42 (19) 28 (10) 41 (21)
80 28 (10) 42 (21) 25 (14) 42 (21)
100 29 (11) 36 (23) 29 (9) 43 (19)
120 23 (10) 39 (19) 21 (9) 43 (16)
140 22 (14) 41(21) 19 (10) 38 (21)
160 23 (9) 40 (19) 23 (8) 41 (20)
180 24 (9) 42 (21) 20 (10) 42 (19)
There were no significant differences in relative recovery or blood flow at
any time-point.
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There were also significant correlations between pain
intensity and the levels of 5-HT and glycerol. Interest-
ingly, no sex differences were found in the release of
biomarkers.
No previous study has investigated muscle 5-HT levels
in response to hypertonic saline injection. However, one
study reported that hypertonic saline injection into bicep
muscles induced a release of glutamate [24], in accord-
ance with the findings of the present study. Other stud-
ies reported no release of 5-HT or glutamate in the
masseter muscle after experimental tooth clenching or
acidic saline injection [40,41]. The difference between
studies might be attributed to the differences in method-
ology. In addition, these two experimental pain models
evoked lower levels of pain compared to hypertonic sa-
line in the present study. This indicates that the hyper-
tonic saline model that clinically can be regarded a valid
experimental model for myalgia, also seem to be valid
with respect to glutamate and 5-HT release. Although
the hypertonic saline model, at least to some extent re-
sembled an acute pain condition, one could argue that it
would increase the levels of 5-HT and glutamate, such
as in chronic pain due to its mechanism. Hypertonic sa-
line has been shown to induce pain by activation of so-
dium channels but also by the release of glutamate [24].
Furthermore, another study points out that the pro-
nociceptive effect could possibly be due to the release of
5-HT acting on 5-HT3 –receptors or even by direct
activation of the 5-HT3 –receptors [31].
Several independent studies have shown increased levels
of 5-HT and glutamate in clinical myalgia and positive cor-
relations to muscle pain and tenderness [16,15,42,18,43,19].
In the present study there was a positive correlation
between 5-HT and pain intensity, which was in line with
previous studies [39,44] and strengthens the validity of5-HT as an important biomarker in muscle pain. Other
studies showed a positive correlation between glutamate
and pain in patients with TMD and trapezius myalgia
[19,16]. No such correlation was found in this study after
injection of hypertonic saline, but there was a negative
correlation on the control side between glutamate and
pain level. However, this negative correlation was consid-
ered without significance since the pain evoked by iso-
tonic saline was minimal and there were large variations
in mediator levels.
Interestingly there was also an increased release of
glycerol in response to the hypertonic saline injection in
this study. Previous studies have suggested that glycerol
may be a marker of cell membrane injury [45]. Loss of
energy due to ischemia and/or mitochondrial dysfunc-
tion eventually leads to an influx of calcium and a de-
composition of cell membranes, which liberates glycerol
into the interstitial fluid [45]. Increased levels of glycerol
may also serve as a marker of muscle damage after
surgery [46]. On the other hand, glycerol levels corre-
lated negatively to pain level, which may seem contra-
dictory. However, since there is just limited knowledge
about the relationship between glycerol and muscle pain,
no certain conclusions can be drawn. Hence, further
studies are needed to evaluate any possible relationships
between pain and glycerol.
There was no release of lactate and pyruvate, which was
in line with previous studies, inducing pain in the bicep
muscles and masseter muscle with hypertonic saline and
acidic saline, respectively [24,40]. Other studies reported
increased levels of pyruvate and lactate in patients with
chronic trapezius myalgia [19,43,47-49] and also in pa-
tients with fibromyalgia and chronic widespread pain
[17,50]. In clinical conditions, higher levels of lactate and
pyruvate may be due to changes in the lactate-pyruvate
metabolism. However, experimental pain models might
differ from clinical conditions and do not seem to influ-
ence muscle metabolism, perhaps because of their acute
character. On the other hand, lactate correlated negatively
to pain levels on the control side. As with glutamate, the
significance of this finding is unknowns because of the low
pain level evoked by isotonic saline. In line with previous
studies of patients with chronic trapezius myalgia, there
was no release of glucose [49].
The significant decrease in PPT on both sides after the
microdialysis was not surprising since it has been
described in a previous study [25]. This might be
explained by the trauma caused by the needle and probe
when inserting the catheter, sensitizing the muscle
tissue. Although there are few studies showing reduced
muscle PPTs after hypertonic saline injections, most
studies report no effect on PPTs [51].
One might claim that the release of biomarkers could
have been affected by the insertion of the microdialysis
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tate, pyruvate and 5-HT return to baseline levels within
1 hour after insertion of the microdialysis catheters
[44,52]. Therefore, a stabilization period of 2 hours
should have been sufficient. This is also a time frame
commonly used for the trauma phase in other studies
[18,19,17]. Another issue could be that we used topical
anesthetics (EMLA cream) to anesthetize the skin before
insertion of the microdialysis catheter, which possibly
might influence the interstitial muscle levels of bio-
markers. However, this is unlikely since a previous study
has shown that EMLA cream applied for 30 minutes on
the forearms did not penetrate deeper than 2.5 mm [53].
This is insufficient to affect the underlying masseter
muscle, hence the local anesthesia most likely had no
effect on the reported release of biomarkers.
Although RR was slightly higher at the beginning of
the microdialysis, the magnitude in general was in line
with previous studies using similar microdialysis probes
[41,44]. This indicates that the calculated interstitial
levels of the substances were comparable between stud-
ies. However, the RR was lower than in studies of other
muscles where a much longer probe could be used. This
was not surprising since it is well known that the RR,
among other factors, depends on the size of the mem-
brane area [18,19,17].
There were no changes in the blood flow after injec-
tions. This is in line with previous study [41] in which
experimental pain was induced by repeated tooth
clenching. However, it cannot be excluded that blood
flow change might have occurred, but could not be
detected, since the dialysates were sampled every 20th
minute. Minute changes might therefore be undetectable.
In this study there were no sex differences regarding
the release of biomarkers. A previous study from this re-
search group where microdialysis was performed during
an experimental pain setting with acidic saline showed
significantly more samples with detectable levels of 5-
HT in women than men [40]. However, as in the present
study, the levels of 5-HT (and the other biomarkers) did
not differ between sexes. One could argue that the sam-
ple size was too small to detect sex differences, which
was a limitation of the study. Indeed, the study was
primarily powered to detect changes in mediator levels
after hypertonic saline for the group as a whole. How-
ever, tendencies were not even detected in sex differ-
ences related to the release of biomarkers, suggesting
that this may be a true finding. Moreover, even if a
much stronger pain was evoked by hypertonic saline
compared to acidic saline, the VAS peak did not differ
between men and women. This was in line with a
previous study of hypertonic saline-induced masseter
myalgia in a sample of similar size [34]. On the other
hand, that study reported twice as large pain area in thewomen. In addition in this study women reported a
larger pain area, although the difference between sexes
was smaller and did not reach significance.
Conclusion
The results of this study showed that a single injection
of hypertonic saline in the human masseter muscle
evoked muscle pain and an increased muscle release of
5-HT, glutamate and glycerol, but there were no sex
differences. Since increased levels of 5-HT and glutamate
have been reported in chronic myalgia, this strengthens
the validity of the pain model.
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